Innoviva Long Term Debt 2012-2025 | INVA
Innoviva long term debt from 2012 to 2025. Long term debt can be defined as the sum of all long term debt fields.
|
Innoviva Annual Long Term Debt (Millions of US $) |
|
|---|---|
| 2024 | $256 |
| 2023 | $446 |
| 2022 | $444 |
| 2021 | $395 |
| 2020 | $386 |
| 2019 | $377 |
| 2018 | $383 |
| 2017 | $574 |
| 2016 | $708 |
| 2015 | $733 |
| 2014 | $726 |
| 2013 | $288 |
| 2012 | $173 |
| 2011 | $173 |
|
Innoviva Quarterly Long Term Debt (Millions of US $) |
|
|---|---|
| 2025-09-30 | $257 |
| 2025-06-30 | $257 |
| 2025-03-31 | $257 |
| 2024-12-31 | $256 |
| 2024-09-30 | $256 |
| 2024-06-30 | $447 |
| 2024-03-31 | $447 |
| 2023-12-31 | $446 |
| 2023-09-30 | $446 |
| 2023-06-30 | $445 |
| 2023-03-31 | $445 |
| 2022-12-31 | $444 |
| 2022-09-30 | $444 |
| 2022-06-30 | $443 |
| 2022-03-31 | $443 |
| 2021-12-31 | $395 |
| 2021-09-30 | $392 |
| 2021-06-30 | $390 |
| 2021-03-31 | $388 |
| 2020-12-31 | $386 |
| 2020-09-30 | $383 |
| 2020-06-30 | $381 |
| 2020-03-31 | $379 |
| 2019-12-31 | $377 |
| 2019-09-30 | $389 |
| 2019-06-30 | $387 |
| 2019-03-31 | $385 |
| 2018-12-31 | $383 |
| 2018-09-30 | $381 |
| 2018-06-30 | $487 |
| 2018-03-31 | $485 |
| 2017-12-31 | $574 |
| 2017-09-30 | $578 |
| 2017-06-30 | $639 |
| 2017-03-31 | $702 |
| 2016-12-31 | $708 |
| 2016-09-30 | $719 |
| 2016-06-30 | $722 |
| 2016-03-31 | $735 |
| 2015-12-31 | $733 |
| 2015-09-30 | $744 |
| 2015-06-30 | $738 |
| 2015-03-31 | $732 |
| 2014-12-31 | $726 |
| 2014-09-30 | $705 |
| 2014-06-30 | $738 |
| 2014-03-31 | $288 |
| 2013-12-31 | $288 |
| 2013-09-30 | $288 |
| 2013-06-30 | $460 |
| 2013-03-31 | $460 |
| 2012-12-31 | $173 |
| 2012-09-30 | $173 |
| 2012-06-30 | $173 |
| 2012-03-31 | $173 |
| 2011-12-31 | $173 |
| 2011-09-30 | $173 |
| 2011-06-30 | $173 |
| 2011-03-31 | $173 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.697B | $0.359B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $983.199B | 42.96 |
| Johnson & Johnson (JNJ) | United States | $586.690B | 22.54 |
| AbbVie (ABBV) | United States | $409.150B | 23.15 |
| Roche Holding AG (RHHBY) | Switzerland | $372.740B | 0.00 |
| Novartis AG (NVS) | Switzerland | $344.536B | 18.16 |
| Merck (MRK) | United States | $301.342B | 13.54 |
| Novo Nordisk (NVO) | Denmark | $221.330B | 12.68 |
| Pfizer (PFE) | United States | $156.812B | 8.54 |
| Sanofi (SNY) | France | $112.219B | 10.39 |
| Bayer (BAYRY) | Germany | $53.369B | 9.37 |